Analyst firms · Robert W. Baird · CLLS

Robert W. Baird CLLS price target and rating history

Cellectis S.A. (CLLS) · Health Care

Robert W. Baird rates Cellectis S.A. (CLLS) Outperform with a $10 price target, as of its latest action on May 18, 2022. It has published 3 rating actions on CLLS since October 2021, including 1 upgrade and 2 downgrades.

Current rating
Outperform
Price target
$10
Median target, all firms
Too few
Actions on CLLS
3

Robert W. Baird price target on CLLS

$40$25$1020222023202420252026
Robert W. Baird price target on CLLS, each point a stated target, October 2021 to May 2022. Targets before October 2021 (multiplied by 4) are adjusted for a stock split, going by the prior target Robert W. Baird restated.

Every Robert W. Baird rating on CLLS

How other firms rate CLLS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$1.30Sep 16, 2026
Citizens JMPMkt PerformSep 15, 2026
JefferiesBuy$7Feb 17, 2026

Questions about Robert W. Baird and CLLS

What is Robert W. Baird's price target for CLLS?
Robert W. Baird's latest stated price target for Cellectis S.A. (CLLS) is $10, from its action on May 18, 2022.
What is Robert W. Baird's rating on CLLS?
Robert W. Baird rates CLLS Outperform, a bullish rating, as of May 18, 2022.
When did Robert W. Baird last change its view on CLLS?
On May 18, 2022, Robert W. Baird upgrades to Outperform from Neutral, price target $10.

All Robert W. Baird ratingsCLLS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.